Search

Search Constraints

You searched for: Author/Creator Guo, Ensong

Search Results

1. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway. (1st March 2022)

2. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity. (February 2023)

3. Cover Image, Volume 41, Issue 12. Issue 12 (23rd December 2021)

4. Front Cover: Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Issue 12 (23rd December 2021)

5. Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. Issue 21 (26th May 2022)

6. Melatonin provides protection against cisplatin-induced ovarian damage and loss of fertility in mice. Issue 3 (March 2021)

7. Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma. Issue 8 (26th June 2022)

8. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Issue 12 (5th November 2021)

10. WEE1 inhibitor and ataxia telangiectasia and RAD3‐related inhibitor trigger stimulator of interferon gene‐dependent immune response and enhance tumor treatment efficacy through programmed death‐ligand 1 blockade. Issue 11 (31st August 2021)